/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Edwards Lifesciences Corporation (EW), a $39.4 billion medical technology firm based in Irvine, California, specializes in cutting-edge solutions for structural heart disease and critical care monitoring. Its product lineup includes tissue heart valves, valve repair systems, hemodynamic monitoring devices, angioscopy tools, oxygenators, and related pharmaceuticals. The company is slated to report its fiscal first-quarter earnings for FY2025 on Thursday, Apr. 24.
Ahead of the event, analysts expect EW to report a profit of $0.60 per share on a diluted basis, down 9.1% from $0.66 per share in the year-ago quarter. The company beat or matched Wall Street’s EPS estimates in all of its last four quarterly reports.